Cargando…

Increased Circulating Levels of PCSK9 and Pro-Atherogenic Lipoprotein Profile in Pregnant Women with Maternal Supraphysiological Hypercholesterolemia

Maternal physiological hypercholesterolemia (MPH) occurs during pregnancy to assure fetal development. Some pregnant women develop maternal supraphysiological hypercholesterolemia (MSPH) characterized by increased levels of low-density lipoprotein (LDL). We aim to determine if proprotein convertase...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cantin, Claudette, Garchitorena, María Jesús, Escalona, Rodrigo, Carvajal, Jorge A., Illanes, Sebastián E., Gutierrez, Jaime, Leiva, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9137759/ https://www.ncbi.nlm.nih.gov/pubmed/35624732 http://dx.doi.org/10.3390/antiox11050869

Ejemplares similares

Maternal Supraphysiological Hypercholesterolemia Is Accompanied by Shifts in the Composition and Anti-Atherogenic Functions of Maternal HDL along with Maternal Cardiovascular Risk Markers at Term of Pregnancy
por: Cantin, Claudette, et al.
Publicado: (2023)

Maternal supraphysiological hypercholesterolemia associates with endothelial dysfunction of the placental microvasculature
por: Fuenzalida, Bárbara, et al.
Publicado: (2018)

Cholesterol uptake and efflux are impaired in human trophoblast cells from pregnancies with maternal supraphysiological hypercholesterolemia
por: Fuenzalida, Bárbara, et al.
Publicado: (2020)

Role for Tetrahydrobiopterin in the Fetoplacental Endothelial Dysfunction in Maternal Supraphysiological Hypercholesterolemia
por: Leiva, Andrea, et al.
Publicado: (2016)

Gestational Diabetes Mellitus Treatment Schemes Modify Maternal Plasma Cholesterol Levels Dependent to Women´s Weight: Possible Impact on Feto-Placental Vascular Function
por: Contreras-Duarte, Susana, et al.
Publicado: (2020)

PCSK9 Antibodies for the Treatment of Hypercholesterolemia
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2014)

Anti-PCSK9 antibodies inhibit pro-atherogenic mechanisms in APOE*3Leiden.CETP mice
por: Schuster, Susanne, et al.
Publicado: (2019)

The elevation of plasma concentrations of apoB-48-containing lipoproteins in familial hypercholesterolemia is independent of PCSK9 levels
por: Drouin-Chartier, Jean-Philippe, et al.
Publicado: (2017)

Lipoprotein-apheresis reduces circulating microparticles in individuals with familial hypercholesterolemia
por: Connolly, Katherine D., et al.
Publicado: (2014)

Anorexia Nervosa Is Associated with a Shift to Pro-Atherogenic Low-Density Lipoprotein Subclasses
por: Stadler, Julia T., et al.
Publicado: (2022)

Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
por: Pęczek, Piotr, et al.
Publicado: (2021)

Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
por: Tomlinson, Brian, et al.
Publicado: (2021)

PCSK9 Inhibitors Reduce PCSK9 and Early Atherogenic Biomarkers in Stimulated Human Coronary Artery Endothelial Cells
por: Zulkapli, Rahayu, et al.
Publicado: (2023)

Streptococcus pneumoniae pneumolysin and neuraminidase A convert high-density lipoproteins into pro-atherogenic particles
por: Syed, Shahan, et al.
Publicado: (2021)

Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease
por: Nozue, Tsuyoshi, et al.
Publicado: (2016)

PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia
por: Ito, Matthew K., et al.
Publicado: (2016)

PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive Synopsis
por: Guo, Qianyun, et al.
Publicado: (2020)

Effect of PCSK9 Inhibitors on Hemostasis in Patients with Isolated Hypercholesterolemia
por: Basiak, Marcin, et al.
Publicado: (2022)

Familial Hypercholesterolemia and Lipoprotein Apheresis
por: Makino, Hisashi, et al.
Publicado: (2019)

Lipoprotein metabolism in familial hypercholesterolemia
por: Chemello, Kévin, et al.
Publicado: (2021)

microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production
por: Dong, Jianjie, et al.
Publicado: (2020)

PCSK9 Inhibitors for the Management of Mitotane-Induced Hypercholesterolemia in Adrenocortical Carcinoma
por: Aurora, John A, et al.
Publicado: (2021)

Effect of a novel nutraceutical combination on serum lipoprotein functional profile and circulating PCSK9
por: Adorni, Maria Pia, et al.
Publicado: (2017)

LDL‐cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid‐lowering therapy
por: Hamasaki, Masato, et al.
Publicado: (2021)

PCSK9 and triglyceride-rich lipoprotein metabolism
por: Druce, Irena, et al.
Publicado: (2015)

Nonalcoholic steatohepatitis is associated with an atherogenic lipoprotein subfraction profile
por: Corey, Kathleen E, et al.
Publicado: (2014)

VLDL receptor gene therapy for reducing atherogenic lipoproteins
por: Krauss, Ronald M., et al.
Publicado: (2023)

Atherogenic Lipoproteins for the Statin Residual Cardiovascular Disease Risk
por: Yanai, Hidekatsu, et al.
Publicado: (2022)

Statins but not fibrates improve the atherogenic to anti-atherogenic lipoprotein particle ratio: a randomized crossover study
por: Chan, Sammy Y, et al.
Publicado: (2008)

Efficacy and Safety of PCSK9 Inhibitors in Hypercholesterolemia Associated With Refractory Nephrotic Syndrome
por: Jatem, Elias, et al.
Publicado: (2020)

The LDLR, APOB, and PCSK9 Variants of Index Patients with Familial Hypercholesterolemia in Russia
por: Meshkov, Alexey, et al.
Publicado: (2021)

PCSK9 immunization using nanoliposomes: preventive efficacy against hypercholesterolemia and atherosclerosis
por: Momtazi-Borojeni, Amir Abbas, et al.
Publicado: (2021)

Angiopoietin-like proteins inhibitors: New horizons in the treatment of atherogenic dyslipidemia and familial hypercholesterolemia
por: Surma, Stanisław, et al.
Publicado: (2023)

Hypercholesterolemia Due to Lipoprotein X: Case Report and Thematic Review
por: Kattah, Laura, et al.
Publicado: (2019)

PCSK9 Inhibition: Does Lipoprotein Size Matter?
por: Si‐Tayeb, Karim, et al.
Publicado: (2015)

Lipoprotein(a) and PCSK9 inhibition: clinical evidence
por: Ruscica, Massimiliano, et al.
Publicado: (2020)

Characterization of Polyvascular Disease in Heterozygous Familial Hypercholesterolemia: Its Association With Circulating Lipoprotein(a) Levels
por: Funabashi, Sayaka, et al.
Publicado: (2022)

Insulin Resistance Predicts Atherogenic Lipoprotein Profile in Nondiabetic Subjects
por: Cartolano, Flávia De C., et al.
Publicado: (2017)

Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis
por: Matta, Anthony, et al.
Publicado: (2021)

Circulating Markers Reflect Both Anti- and Pro-Atherogenic Drug Effects in ApoE-Deficient Mice
por: Liao, Birong, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_nng3jj6d2pm46c816d42vftca2